Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

Part of paid clinical trials in Murray, Utah.

Sponsor
Scott C. Woller, MD
Study ID
NCT06232551
Status
Recruiting
Apply to this trial

Conditions

  • Deep Vein Thrombosis
  • Hospitalism
  • Pulmonary Embolism and Thrombosis
  • Venous Thromboembolic Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - 110 Years
Healthy Volunteers
Not accepted

Interventions

  • EHR (electronic health record) alert — OTHER
    Pop-up alert that informs the discharging clinician that the patient meets criteria to be considered for extended duration thromboprophylaxis
  • No EHR (electronic health record) alert — OTHER
    During the baseline phase while risk is assessed and stored, no alerting occurs

Study Details

A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to decrease their risk of blood clots, and for whom the risk of bleeding is minimal. The purpose of this study is to evaluate the use of a pop-up alert, which will be seen by clinicians when a discharging patient has been identified as being someone for whom the risk of blood clots is high, but for whom bleeding risk is estimated to be low. The pop-up alert will be enabled in a sequential fashion for each group of hospitals in 1 month blocks. We will look to see if the pop-up alert changes the number of patients who receive rivaroxaban. We will also measure the outcomes of blood clots and bleeding among all discharging patients.

Key Dates

Start date
Jun 1, 2024
Status verified
Jul 2024
Primary completion
Jan 15, 2025
Completion
Sep 30, 2025

Study Design

Enrollment
152,000 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • Experimental: At-risk patients for which an alert is sent during the intervention phase
    Patients found to be at an increased risk for VTE but a low risk for bleeding (based upon eVTE risk assessment), thereby meeting criteria for alerting during the intervention phase
  • Active Comparator: At-risk patients during the baseline phase
    Patients found to be at an increased risk for VTE but a low risk for bleeding (based upon eVTE risk assessment), and who meet criteria for alerting, but for whom no alert is sent during the baseline phase

Primary Outcome Measure

Primary outcome (implementation) [ Time Frame: From discharge to 7 days after discharge ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Intermountain Medical CenterMurrayUtah84107
Scott C. Woller, MD
[email protected]
801-507-3376

Find similar trials in Murray, UT

By research site
Intermountain Medical Center· Murray, UT

Related Studies